OXURION (EBR:OXUR) | WebDisclosure

Basculer en Français

10063	Companies
205697	Keywords
135926	Articles
109050	Press releases

Home
Companies
OXURION

PRESS RELEASE

published on 07/17/2025 at 08:30, 8 months 6 days ago

Oxurion Secures Financing for the Acquisition of Axiodis CRO and Targets Closing on August 1, 2025
Oxurion NV secures financing for 72% stake in Axiodis CRO, enhancing its clinical data capabilities. Acquisition aligned with strategic roadmap for European hub. Closing set for August 1, 2025

Acquisition Clinical Data Oxurion NV Axiodis CRO European Hub
PRESS RELEASE

published on 07/17/2025 at 08:30, 8 months 6 days ago

Oxurion verzekert financiering voor de overname van Axiodis CRO en beoogt een closing op 1 augustus 2025
Oxurion sichert Finanzierung für die Übernahme von Axiodis CRO ab und plant Abschluss der Transaktion am 1. August 2025

Übernahme Finanzierung Oxurion Klinische Daten Therapeutische Entwicklung
BRIEF

published on 07/15/2025 at 18:05, 8 months 7 days ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Shares Transparency Atlas Biopharmaceutical Oxurion
BRIEF

published on 07/15/2025 at 18:05, 8 months 7 days ago

Oxurion reçoit une notification de transparence d'Atlas Special Opportunities II LLC

Actions Atlas Transparence Biopharmaceutique Oxurion
PRESS RELEASE

published on 07/15/2025 at 18:00, 8 months 7 days ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Oxurion NV receives transparency notification from Atlas Special Opportunities II, LLC regarding shareholding threshold crossing under Belgian Transparency legislation

Transparency Notification Shareholding Oxurion NV Belgian Legislation Atlas Special Opportunities II LLC
PRESS RELEASE

published on 07/15/2025 at 18:00, 8 months 7 days ago

Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
Oxurion NV meldt ontvangst van transparantiekennisgeving en verlaagd aandelenposities onder wettelijke drempel. Biofarmaceutisch bedrijf in Leuven actief op gebied van therapeutische innovatie en klinisch onderzoek

Transparantiekennisgeving Euronext Brussel Oxurion NV Leuven Biofarmaceutisch
BRIEF

published on 07/14/2025 at 18:05, 8 months 8 days ago

Oxurion Announces Transparency Notifications from Atlas

Biopharmaceutical Shareholder Notification Atlas Special Opportunities Oxurion NV Transparency Legislation
BRIEF

published on 07/14/2025 at 18:05, 8 months 8 days ago

Oxurion annonce les notifications de transparence d'Atlas

Biopharmaceutique Notification Aux Actionnaires Oxurion NV Opportunités Spéciales Atlas Législation Sur La Transparence
PRESS RELEASE

published on 07/14/2025 at 18:00, 8 months 8 days ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
Oxurion NV receives transparency notifications regarding changes in shareholding from Atlas Special Opportunities II, LLC, in accordance with Belgian Transparency legislation

Shareholding Oxurion NV Belgian Legislation Transparency Notifications Atlas Special Opportunities II LLC
PRESS RELEASE

published on 07/14/2025 at 18:00, 8 months 8 days ago

Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
Oxurion NV heeft transparantiekennisgevingen ontvangen volgens de Belgische wetgeving betreffende belangrijke deelnemingen. Atlas Special Opportunities II LLC heeft aanzienlijke aandelen in Oxurion verworven en verkocht. Raadpleeg www.oxurion.com voor meer informatie

Transparantiekennisgevingen Oxurion NV Biofarmaceutisch Belgische Wetgeving Atlas Special Opportunities II LLC

Accesswire

Published on 03/23/2026 at 08:00, 3 hours 5 minutes ago

ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
Published on 03/23/2026 at 02:00, 9 hours 5 minutes ago

FutureGen Industries Announces Open Market Investments
Published on 03/20/2026 at 23:00, 2 days 12 hours ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 2 days 13 hours ago

Sky Gold Sets Options
Published on 03/20/2026 at 21:15, 2 days 13 hours ago

Earthwise Minerals Announces Private Placement

View all ACCESSWIRE

EQS Group

Published on 03/23/2026 at 10:30, 35 minutes ago

TK Elevator appoints Brad Selleck as Chief Operating Officer; Vincent Della Valle to retire
Published on 03/23/2026 at 10:30, 35 minutes ago

TK Elevator creates the role of Chief Legal Officer, appoints Lars Sjobring
Published on 03/23/2026 at 09:19, 1 hour 46 minutes ago

Mister Spex Chooses Salesforce to further develop its Omnichannel Strategy
Published on 03/23/2026 at 09:00, 2 hours 5 minutes ago

Removal: Tower Bridge Funding 2022-1 PLC
Published on 03/23/2026 at 09:00, 2 hours 5 minutes ago

Removal: Imara Gold plc

Les Echos

Published on 03/23/2026 at 08:10, 2 hours 55 minutes ago

Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 16 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 16 hours ago

AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 16 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 16 hours ago

Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA

View all LES ECHOS COMFI WIRE